{"id":21552,"date":"2025-01-14T22:00:13","date_gmt":"2025-01-14T14:00:13","guid":{"rendered":"https:\/\/flcube.com\/?p=21552"},"modified":"2025-01-14T22:00:15","modified_gmt":"2025-01-14T14:00:15","slug":"novartis-to-defend-entresto-patent-after-cafc-ruling","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21552","title":{"rendered":"Novartis to Defend Entresto Patent After CAFC Ruling"},"content":{"rendered":"\n

Novartis (NYSE: NVS<\/a>) has revealed a favorable decision by the US Court of Appeals for the Federal Circuit (CAFC), affirming the validity of the Entresto (sacubitril\/valsartan) combination patent. This decision comes as the pediatric exclusivity period for the combination patent is set to expire in July 2025. The Swiss pharmaceutical giant has vowed to continue defending and protecting all its important intellectual property and regulatory rights relating to Entresto, a drug for which no generic version is currently approved in the United States.<\/p>\n\n\n\n

Background on Patent Challenge<\/strong>
India-based firm MSN Laboratories previously challenged the Entresto patent in the US. In response, Novartis filed a lawsuit against MSN and other companies planning to produce generic versions of Entresto back in 2022. Novartis claimed that these proposed products infringed a patent that expires in 2026.<\/p>\n\n\n\n

Recent CAFC Decision and Novartis Response<\/strong>
According to a Reuters report last month, the CAFC had rejected Novartis’ request to block MSN from launching a generic version of the drug in the United States. Novartis expressed disappointment with the ruling, stating that it “disagrees with this decision” and is “considering all feasible options to actively defend our intellectual property, including the possibility of further appeal.”-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for…<\/p>\n","protected":false},"author":1,"featured_media":21553,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[61],"tags":[69,140,865],"class_list":["post-21552","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-legal-ip","tag-cvd","tag-novartis","tag-nyse-nvs"],"yoast_head":"\nNovartis to Defend Entresto Patent After CAFC Ruling - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for the Federal Circuit (CAFC), affirming the validity of the Entresto (sacubitril\/valsartan) combination patent. This decision comes as the pediatric exclusivity period for the combination patent is set to expire in July 2025. The Swiss pharmaceutical giant has vowed to continue defending and protecting all its important intellectual property and regulatory rights relating to Entresto, a drug for which no generic version is currently approved in the United States.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21552\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis to Defend Entresto Patent After CAFC Ruling\" \/>\n<meta property=\"og:description\" content=\"Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for the Federal Circuit (CAFC), affirming the validity of the Entresto (sacubitril\/valsartan) combination patent. This decision comes as the pediatric exclusivity period for the combination patent is set to expire in July 2025. The Swiss pharmaceutical giant has vowed to continue defending and protecting all its important intellectual property and regulatory rights relating to Entresto, a drug for which no generic version is currently approved in the United States.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21552\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-14T14:00:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-14T14:00:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1408-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21552#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21552\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis to Defend Entresto Patent After CAFC Ruling\",\"datePublished\":\"2025-01-14T14:00:13+00:00\",\"dateModified\":\"2025-01-14T14:00:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21552\"},\"wordCount\":208,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21552#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1408-1.png\",\"keywords\":[\"CVD\",\"Novartis\",\"NYSE: NVS\"],\"articleSection\":[\"Legal \\\/ IP\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21552#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21552\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21552\",\"name\":\"Novartis to Defend Entresto Patent After CAFC Ruling - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21552#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21552#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1408-1.png\",\"datePublished\":\"2025-01-14T14:00:13+00:00\",\"dateModified\":\"2025-01-14T14:00:15+00:00\",\"description\":\"Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for the Federal Circuit (CAFC), affirming the validity of the Entresto (sacubitril\\\/valsartan) combination patent. This decision comes as the pediatric exclusivity period for the combination patent is set to expire in July 2025. The Swiss pharmaceutical giant has vowed to continue defending and protecting all its important intellectual property and regulatory rights relating to Entresto, a drug for which no generic version is currently approved in the United States.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21552#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21552\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21552#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1408-1.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1408-1.png\",\"width\":1080,\"height\":720,\"caption\":\"Novartis to Defend Entresto Patent After CAFC Ruling\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21552#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis to Defend Entresto Patent After CAFC Ruling\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis to Defend Entresto Patent After CAFC Ruling - Insight, China's Pharmaceutical Industry","description":"Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for the Federal Circuit (CAFC), affirming the validity of the Entresto (sacubitril\/valsartan) combination patent. This decision comes as the pediatric exclusivity period for the combination patent is set to expire in July 2025. The Swiss pharmaceutical giant has vowed to continue defending and protecting all its important intellectual property and regulatory rights relating to Entresto, a drug for which no generic version is currently approved in the United States.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21552","og_locale":"en_US","og_type":"article","og_title":"Novartis to Defend Entresto Patent After CAFC Ruling","og_description":"Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for the Federal Circuit (CAFC), affirming the validity of the Entresto (sacubitril\/valsartan) combination patent. This decision comes as the pediatric exclusivity period for the combination patent is set to expire in July 2025. The Swiss pharmaceutical giant has vowed to continue defending and protecting all its important intellectual property and regulatory rights relating to Entresto, a drug for which no generic version is currently approved in the United States.","og_url":"https:\/\/flcube.com\/?p=21552","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-14T14:00:13+00:00","article_modified_time":"2025-01-14T14:00:15+00:00","og_image":[{"width":1080,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1408-1.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21552#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21552"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis to Defend Entresto Patent After CAFC Ruling","datePublished":"2025-01-14T14:00:13+00:00","dateModified":"2025-01-14T14:00:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21552"},"wordCount":208,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21552#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1408-1.png","keywords":["CVD","Novartis","NYSE: NVS"],"articleSection":["Legal \/ IP"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21552#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21552","url":"https:\/\/flcube.com\/?p=21552","name":"Novartis to Defend Entresto Patent After CAFC Ruling - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21552#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21552#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1408-1.png","datePublished":"2025-01-14T14:00:13+00:00","dateModified":"2025-01-14T14:00:15+00:00","description":"Novartis (NYSE: NVS) has revealed a favorable decision by the US Court of Appeals for the Federal Circuit (CAFC), affirming the validity of the Entresto (sacubitril\/valsartan) combination patent. This decision comes as the pediatric exclusivity period for the combination patent is set to expire in July 2025. The Swiss pharmaceutical giant has vowed to continue defending and protecting all its important intellectual property and regulatory rights relating to Entresto, a drug for which no generic version is currently approved in the United States.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21552#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21552"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21552#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1408-1.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1408-1.png","width":1080,"height":720,"caption":"Novartis to Defend Entresto Patent After CAFC Ruling"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21552#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis to Defend Entresto Patent After CAFC Ruling"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1408-1.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21552"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21552\/revisions"}],"predecessor-version":[{"id":21554,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21552\/revisions\/21554"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21553"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}